Key Highlights

  • Revenue was $209.3 million, up 11% reported and 12.5% organic, versus a $206.7 million researcher estimate.
  • Adjusted EBITDA reached $43.8 million, a 20.9% margin versus 19.0% a year earlier.
  • A $41.2 million intangible asset impairment produced a GAAP loss of $0.68 per share.
  • With adjusted EPS of $2.05 to $2.09, Full-year 2026 revenue outlook is $844 million to $852 million.
  • Adjusted diluted EPS was $0.53 versus $0.46 a year earlier, versus the $0.46 projection as screened (14.49% over).

Which Repligen Earnings Detail Could Set the Tone From Here?

With adjusted diluted EPS of $0.53, up from $0.46 and over the $0.46 projection as screened, Repligen (NASDAQ:RGEN) reported third-quarter figures on Tuesday, October 27. Revenue of $209.3 million advanced from $188.8 million, ahead of the $206.7 million researcher projection. Management increased full-year outlook again.

The swing was driven by a $41.2 million intangible asset impairment, which pushed the GAAP loss from operations to $29.5 million from income of $16.8 million. GAAP net loss was $38.4 million. On a GAAP basis the quarter was a loss of $0.68 per share, versus earnings of $0.26 a year earlier.

Which Growth Driver Could Matter Most for Repligen?

The acquisition and divestiture impact added 1 point and currency added 1 point. Repligen supplies filtration, chromatography and analytics products used to make biologic drugs. With organic growth of 12.5% in the release highlights (12% in the reconciliation table), Reported revenue growth was 11%.

Adjusted EBITDA was $43.8 million, a 20.9% margin versus 19.0%, and adjusted net income was $29.9 million versus $25.9 million. Adjusted operating income moved higher to $33.3 million from $26.8 million, lifting the adjusted operating margin to 15.9% from 14.2%.

Gross margin was little changed. 53.0% GAAP versus 53.2%, and 53.0% adjusted versus 53.3%.

How Might the New Deal Change Repligen's Financial Picture?

Gross margin is projected at 53.7% to 54.2% and income from operations at $135 million to $139 million, a 16.0% to 16.3% operating margin. The updated 2026 outlook calls for total revenue of $844 million to $852 million, reported growth of 14.5% to 15.5% and organic growth of 12% to 13%.

The range includes BioLife from its October 6 closing date, assumes neutral currency, and carries approximately 2.5 points of inorganic benefit net of the Polymem divestiture. The release gives no separate fourth-quarter range. With an adjusted EBITDA margin close to 21% and a tax rate close to 22%, adjusted net income is guided to $119 million to $122 million, or $2.05 to $2.09 per diluted share.

With healthy consumables and services trends and a growing capital equipment order book, management stated end-market appetite continues to improve. It linked the outlook raise to year-to-date performance, order momentum and the BioLife addition, and stated integration is progressing with a sizable portion of projected operating expense synergies already in motion.

Which Deal Term Could Set the Next Direction for Repligen?

Nine-month revenue was $607.7 million versus $540.3 million, adjusted EPS was $1.55 versus $1.23, and adjusted EBITDA was $127.6 million, a 21.0% margin versus 18.7%. Cash, cash equivalents and marketable securities were $863 million at September 30, up from $768 million at year-end.

The release does not describe buybacks or a dividend. Nine-month GAAP EPS was a loss of $0.44 versus earnings of $0.63, reflecting the impairment.

What Is the Next Earnings Test for Repligen?

The next checkpoints are the fourth-quarter results, where BioLife contributes a first partial quarter, the pace of the synergies management described, and whether the 53.0% gross margin shifts toward the 53.7% to 54.2% full-year range.